Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Diagnosis

Y-90 microspheres treatment response monitoring: PET/CT or diagnostic MR ?

Uliyana Yankevich, Peter Faulhaber, Chaitra Badve and James ODonnell
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1335;
Uliyana Yankevich
1Radiology, University Hospitals Case Medical Center, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Faulhaber
1Radiology, University Hospitals Case Medical Center, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chaitra Badve
1Radiology, University Hospitals Case Medical Center, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James ODonnell
1Radiology, University Hospitals Case Medical Center, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1335

Objectives The intra-arterial administration of Y-90 microspheres is a new palliative treatment for unresectable liver malignancies. However, there is no widely accepted imaging protocol for treatment response monitoring. Our aim was to compare the accuracy of FDG-PET/CT and a standard-protocol liver MR in evaluating response to Y-90 microspheres embolisation.

Methods We evaluated 25 patients who underwent Y-90 microspheres embolisation (SIR-Spheres, Sirtex Medical Ltd., Sydney, Australia) for pathologically proven liver malignancy. Baseline imaging studies prior to treatment as well as post-treatment CT, MR, or PET/CT scans were reviewed. A subset of 4 patients had post-treatment MR and PET/CT scans not more than 1 mo apart. Both studies were examined in comparison to each other and against the results of long-term clinical or imaging follow-up to determine if PET/CT is more accurate than MR in defining treatment response and directing patient management.

Results 25 patients were treated with SIR-Spheres in our institution in the above time interval. 4 patients were treated for primary liver malignancy; the others had metastatic liver disease. All patients had diagnostic liver MR 4 to 8 weeks after the treatment. 4 patients also had FDG-PET/CT scan performed not more than 4 weeks apart from the MR. In 3 out of 4 patients, the MRI demonstrated grossly stable appearance of the liver when compared to pre-treatment imaging suggestive of stable liver disease, whereas PET/CT showed no hypermetabolic activity in the treated lesions consistent with no residual disease. None of these patients had liver disease recurrence in the next 22 months. In 1 patient, both modalities showed metastatic disease progression, which was confirmed by CT follow up 3 months later.

Conclusions FDG-PET/CT imaging may be a more accurate assessment of therapy response following Y-90 microspheres embolisation than liver MR; larger cohort of patients is currently under evaluation.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Y-90 microspheres treatment response monitoring: PET/CT or diagnostic MR ?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Y-90 microspheres treatment response monitoring: PET/CT or diagnostic MR ?
Uliyana Yankevich, Peter Faulhaber, Chaitra Badve, James ODonnell
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1335;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Y-90 microspheres treatment response monitoring: PET/CT or diagnostic MR ?
Uliyana Yankevich, Peter Faulhaber, Chaitra Badve, James ODonnell
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1335;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Diagnosis

  • Benefits of dedicated hepatic imaging using simultaneous PET/MRI
  • 3D Volumetric lymph node assessment based on CT versus PSMA-PET/CT in recurrent prostate cancer
  • Impact of a high-resolution reconstruction using state-of-the-art PET/CT on intra-thoracic lymph node staging
Show more Oncology: Clinical Diagnosis

MTA I: GI-Colorectal & Liver Posters

  • Post-treatment 18F-FDG PET /CT predicts progression-free and cause-specific survival in patients with anal carcinoma
  • Usefulness of FDG PET/CT dual point images to detect liver lesions
  • Is systematic colonoscopy of incidental colonic uptakes detected by 18F-FDG PET/CT safe and always indicated?
Show more MTA I: GI-Colorectal & Liver Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire